

1 **Polygenic Risk Score predicts QTc-prolongation and Short-Term**
2 **Mortality in Patients using QT-prolonging Psychoactive**
3 **Medications**

4
5 Mays Altaraihi¹²

6
7 Affiliations:

8 ¹ Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen,
9 Denmark

10 ² Laboratory for Molecular Cardiology, Department of Biomedical Sciences, University of
11 Copenhagen, Copenhagen, Denmark

12
13 Corresponding Author: Mays Altaraihi, m.altaraihi@gmail.com

14
15 Total word count: 4401 Abstract word count: 247; Figures: 4; Tables: 7

16

17 **Abstract**

18 **Background:**

19 There is a genetic component to the QT-interval. This study investigated whether a polygenic
20 risk score for QTc (PRS_{QTc}) could predict Δ QTc and short-term mortality in first-time users of
21 QT-prolonging medications (QTPM) with a known risk of Torsade de Pointes.

22 **Methods:**

23 First-time users of psychoactive QTPM in the Copenhagen Hospital Biobank and the Danish
24 Blood Donor Study from 2009-2021 were included. Δ QTc was calculated and all-cause 30-day
25 mortality following initiation of treatment was explored. All models were adjusted for
26 conventional QT-prolonging risk factors, and models investigating death were additionally
27 adjusted for potential comorbidity confounders.

28 **Results:**

29 The PRS_{QTc} could predict Δ QTc (2.88 milliseconds (ms) for every increase of standard
30 deviation in PRS_{QTc} (P <0.001)) following treatment initiation. Individuals in the top ≥ 80 % of
31 PRS_{QTc} had a higher risk of Δ QTc of ≥ 60 ms compared to individuals in <80 % PRS_{QTc} (OR =
32 4.88 P = 0.019). Furthermore, the study has also shown that the shorter QTc before initiation
33 of QTPM, the higher the risk of greater Δ QTc.

34 A high PRS_{QTc} could also predict short-term mortality following treatment initiation:

35 Individuals in the top PRS_{QTc} ≥ 90 % had an odds ratio of 1.84 (P-value = 0.002) for short-term
36 mortality compared to individuals with PRS_{QTc} <90 %. Individuals in the top PRS_{QTc} ≥ 99 %
37 had an odds ratio of 4.95 (P-value = 0.009) for short-term mortality compared to individuals
38 in the <99 % PRS_{QTc}

39 It could be replicated that PRS_{QTc} ≥ 90 % was a predictor of short-term mortality with OR 1.52
40 (P-value = 0.002) compared to PRS_{QTc} <90 % in a bigger cohort (N=15.249).

41 **Conclusion:**

42 PRS_{QTc} seems to be predictive of Δ QTc following initiation of treatment. PRS_{QTc} proves to be a
43 sufficient predictor of 30-day mortality after initiation of QT-prolonging psychoactive drugs
44 with a known risk of Torsade de Pointes.

45 If used in a clinical setting, PRS_{QT} may help prevent sudden cardiac deaths associated with
46 QTPM.

47

48 **Keywords:** QT-interval, QT-prolongation, QT-prolonging drugs, QT-prolonging medication,
49 QTc, psychoactive drugs, psychoactive medication, psychotropic drugs, psychotropic
50 medication, polygenic risk score, ECG, torsade de pointes, torsades de pointes, sudden cardiac
51 death
52

53 **Introduction**

54 The electrocardiographic QT-interval represents the sum of the ventricular depolarization and
55 repolarization. The QT-interval is clinically important as both a long and a short QT-interval
56 predisposes to ventricular arrhythmias and sudden cardiac death. Many commonly prescribed
57 drugs (QT-prolonging medication, QTPM) may cause QT-interval prolongation and thereby
58 increase the risk of developing Torsade de Pointes (TdP) which predisposes to sudden cardiac
59 death (1–3). Therefore, evaluation of drug-induced QT-prolongation is crucial when
60 developing, testing, and prescribing drugs.

61
62 The mechanisms of drug-induced long QT involve the drug's interaction with several cardiac
63 ion channels, in which the main interaction is a blockade of the rapid potassium current (I_{Kr})
64 encoded by the gene *KCNH2*. The final manifestation of the drug-ion-channel interactions is a
65 reduction of the net repolarization current in the ventricular action potential, leading to QT-
66 prolongation (4,5). Another important risk factor of QT-prolongation is hypokalemia(6,7). Not
67 all patients develop prolonged QT-interval when exposed to the same QTPM and this
68 variability in response is partly ascribed to genetic factors (8). Indeed, studies show that
69 variants in genes encoding the cardiac channels can modify the drug-channel interaction,
70 resulting in an increase of the binding affinity or the channel gating kinetics (9,10). Genome-
71 wide association studies (GWAS) of the QT-interval have been conducted to explain the
72 heritability of the QT-interval in the general population. Studies show that polygenic risk
73 scores calculated based on GWASs of corrected QT-interval (PRS_{QTc}) associate significantly
74 with long QT-syndrome in genotype negative individuals and sudden cardiac death (2,11).

75
76 This study hypothesized that PRS_{QTc} may predict the variability in response to QTPM. By
77 designing a case-control study, the aim of the current study was to investigate if individuals in
78 the top quantile of PRS_{QTc} are at greater risk of prolonged QT-interval following initiation of
79 QT-prolonging psychoactive medication with a known risk of TdP. Subsequently, the aim was
80 also to investigate whether individuals belonging in the top quantile of PRS_{QTc} are at greater
81 risk of 30-day-mortality following the initiation.

82

83

84

85 **Methods**

86

87 **Study Design and Population**

88 The study is based on the Copenhagen Hospital Biobank (CHB)(12) initiated in February 2009
89 and the Danish Blood Donor Study (DBDS)(13) initiated in March 2010. First-time users of
90 psychoactive drugs listed on CredibleMeds (14) as QTPM with a known risk of TdP from 2009-
91 2021 were included. These drugs will hereby be referred to as reference drugs. The following
92 reference drugs were investigated: Citalopram, Haloperidol, Escitalopram, Methadone,
93 Chlorprothixene, Levomepromazine, Pimozide, Sulpiride and Sertindole. For inclusion, the
94 drugs had to be tablets or capsules intended for oral administration.

95 Twelve lead ECGs were obtained per clinical indication and integrated in the CHB/DBDS
96 environment. Based on the Marquette 12SL algorithm used in the ECGs, ECGs not consistent
97 with a valid measurement of the QT-interval (e.g., branch blocks, atrial fibrillation,
98 bradycardia, see Supplementary for ECG details) were excluded.

99 Apart from being first-time users of reference drugs, included individuals had to be registered
100 with ECGs with valid measurements of the QT-interval. When exploring the outcome, ΔQTc ,
101 individuals had to be registered with at least two valid ECGs: At least one ECG measured
102 within 18 months before the first prescription of the reference drug (baseline-ECG) and at
103 least one ECG measured within 18 months after the first prescription (treatment-ECG). If
104 more than one baseline-ECGs were present, the ECG closest to the date of the first prescription
105 was used. If more than one after-ECGs were present, the ECG closest to day 15 after the first
106 prescription was used. Furthermore, only individuals with after-ECGs, in which the ECG was
107 measured within the treatment period, were included. For more details on calculation of the
108 treatment period, see Supplementary. When investigating short-term mortality, only a valid
109 baseline-ECG was required to be included.

110 Lastly, using the latest blood test, all included individuals had to be registered with a
111 potassium blood test within 4 months before the first prescription of the reference drug.

112 Figure 1 and Figure 2 illustrate the methods used.

113

114

115

116 **Genetics**

117 GWAS summary statistics on Fridericia-corrected QT-interval (QTcF) from previous published
118 data were queried (15). Using PRS-CS (16), individual polygenic risk in CHB/DBDS was
119 calculated. In CHB/DBDS, individuals were genotyped on Infinium Global Screening Array
120 (Illumina Inc, USA). In sample-wise quality control of CHB/DBDS, samples with missingness <
121 97%, sex mismatch, genetic ancestry outliers and heterozygosity outliers (>3SD) were
122 removed. In marker-wise QC, variants with missingness < 99%, low Hardy-Weinberg
123 equilibrium ($P < 0.0001$), and minor allele frequency < 0.1% were removed. Imputed genetic
124 data with an information quality cutoff < 0.9 were used to create genotype files for individuals
125 in CHB/DBDS.

126

127 **Other covariates**

128 For model adjustment, the following conventional risk factors for prolonged QT-interval were
129 investigated:

130 Age. Sex. Hypokalemia (plasma-Potassium <3.6 mmol/L). Loop-diuretics or thiazides without
131 potassium: If prescribed within 30 days before prescription of the reference drug had been
132 filled, the individuals were registered as being on diuretic treatment (17).

133 To explore the additive effect of QTPM on the outcome, it was investigated whether the
134 individuals had a prescription of another QT-prolonging psychoactive medication with a
135 *possible* risk of Torsade de Pointes according to CredibleMeds (14). The prescription of the
136 other QTPM had to be within 30 days before the prescription of the reference drug. The
137 additional QT-prolonging psychoactive medication could be one of the following drugs:
138 Mirtazapine, Nortriptyline, Misanserine, Fluanxol, Clozapine, Aripiprazole, Perphenazine,
139 Melperone, Maprotiline and Pipamperone.

140 Models were adjusted for heart failure, using all diagnosis codes for heart failure. When
141 addressing ischemic heart disease (IHD), both disease diagnoses and/or procedure codes
142 involved in ischemic heart diseases were used: Ischemic myocardial infarction diagnoses
143 (IHD) percutaneous coronary intervention or coronary artery bypass grafting (18).

144

145 Inhibited drug clearance due to hepatic or renal dysfunction can prolong the QT-interval when
146 exposed to QTPM. Therefore, hepatic or renal insufficiency before prescription of the
147 reference drug was included as a covariate. Diagnosis codes for hepatic failure chronic

148 hepatitis, fibrosis/cirrhosis of the liver, acute kidney failure, chronic kidney disease or
149 unspecified kidney failure were used (19).

150 For short-term mortality, the models were adjusted for the most common mortality causes in
151 high-income countries: Cancer, IHD, stroke and chronic obstructive pulmonary disease
152 (COPD). Cancer was defined as all cancers except non-malignant melanoma skin cancer.
153 All the used diagnosis and procedure codes had to be registered before the prescription of the
154 reference drug. All the ATC, diagnosis and procedure codes can be found in Supplementary.

155

156 **Outcomes**

157 The outcome, ΔQTc , was defined as the absolute difference of measured $QTcF$ in treatment-
158 ECG and baseline-ECG. The outcome, ΔQTc , was investigated in a linear regression model
159 adjusted for covariates. The outcome, ΔQTc , was also investigated as a binary outcome in
160 adjusted logistic models, using $\Delta QTc \geq 10$ ms, ≥ 20 ms, ≥ 30 ms, ≥ 40 ms, ≥ 50 ms and ≥ 60 ms.
161 The binary ΔQTc outcomes were investigated in an interaction analysis, exploring the
162 interaction between PRS_{QTc} and the $QTcF$ in the baseline-ECG.

163 Short-term mortality was defined as death within 30 days after the first filled prescription of
164 the reference drug. The death had to occur during the treatment period. In addition, only
165 deaths registered to be of natural causes were registered as outcomes, excluding suicides,
166 homicides, accidents, and unknown causes. The decision to use 30-day-mortality as outcome
167 is based on the risk of drug-induced TdP being greatest during the following days after
168 initiation of QTPM (18).

169 To address ascertainment bias, short-term mortality was tested as outcome in a cohort not
170 limited by the need of ECGs and potassium blood tests prior to initiation of the reference drug.
171 In this cohort, all individuals with the diagnosis atrial fibrillation or atrial flutter were
172 excluded, as atrial fibrillation reduces the likelihood of TdP after initiation of QTPM(20).

173

174 **Statistics**

175 The case-control association analysis was performed using linear and logistic regression with
176 the generalized linear model (GLM). The results are shown as ΔQTc in milliseconds or odds
177 ratios with belonging confidence intervals and P-values. When calculating statistically
178 significant differences of continuous outcomes in separate groups, the Mann-Whitney U test

179 was used. If the outcomes were binary, Chi-squared test was used. In the latter two tests, only
180 the P-values are shown in this study.

181

182 **Results**

183 **Δ QTc**

184 The cohort exploring the outcome, Δ QTc, consisted of 785 first-time users of QTPM meeting
185 the inclusion criteria. This study found that for every increase in standard deviation (s.d.) of
186 PRS_{QTc}, Δ QTc would increase with 2.88 ms (P <0.001) (table 1 and figure 3).

187 The binary traits Δ QTc \geq 10 ms, \geq 20 ms, \geq 30 ms, \geq 40 ms, \geq 50 ms and \geq 60 ms (table 2) were
188 examined. Individuals in the top \geq 80 % PRS_{QTc} had greater risk of Δ QTc \geq 60 ms compared to
189 individuals with PRS_{QTc} <80 % (OR = 4.88, P = 0.019). Results from the interaction analysis
190 showed that individuals with normal QTc in the baseline-ECG (380-449 ms (M)/390-459 ms
191 (F)) were at greatest risk of higher Δ QTc compared to those with borderline QTc (QTcF 450-
192 496 ms (M)/460-479 ms) or prolonged QTc (470 ms (M)/ \geq 480 ms (F)) in the baseline-ECG
193 (table).

194 The study has also shown that the shorter QTc before initiation of QTPM, the higher the risk of
195 greater Δ QTc (figure 4). This is in line with an Icelandic study showing that the shorter QTc
196 before surgery, the higher the risk of greater Δ QTc postoperative (21).

197

198 **Short-term mortality**

199 In the studied population consisting of 3001, PRS_{QTc} \geq 80 % could predict short-term mortality
200 with OR 1.32 (P-value = 0.089), PRS_{QTc} \geq 90 % could predict short-term mortality with OR 1.84
201 (P-value = 0.002) and PRS_{QTc} \geq 99 % could predict short-term mortality with OR 4.95 (P-value
202 = 0.0093) (table 5). All the reported results originate from adjusted models including PCs 1-
203 10, age, sex, heart failure, IHD, loop diuretics/thiazides, additional QTc-prolonging medication,
204 renal insufficiency, hepatic insufficiency, hypokalemia, baseline QTcF, cancer, stroke and COPD.

205

206 A forest plot showing AUC of the different risk factors for prolonged QTc/mortality is
207 illustrated in figure 5. When analyzing the AUC difference of all risk factors except PRS_{QTc} \geq
208 90 % and all risk factors including PRS_{QTc} \geq 90 % , the difference is statistically significant,
209 though not robust, with a P-value of 0.04.

210 This study also found that longer baseline QTcF seems to be protective of 30-day-mortality
211 following initiation of the reference drug: QTcF, OR 0.99 (P-value = 0.0029).

212 When analyzing the deceased individuals, the ones in the top PRS_{QTc} quantiles are slightly
213 younger than the rest: For instance, individuals belonging to the PRS_{QTc} ≥ 99 %, the mean age
214 at death 64.3 years and individuals belonging to PRS_{QTc} < 99 %, the mean age at death was
215 74.9 years (P-value = 0.028) (table 7).

216 Another finding is the increased prevalence of cancer in the top PRS_{QTc} quantiles (table 5): For
217 instance, the prevalence of cancer in PRS_{QTc} ≥80 % is 42.5 % and 33.9 % in the PRS_{QTc} < 80 %
218 group (P-value = 0.0001). In the deceased individuals, cancer was not significantly more
219 prevalent in the top PRS_{QTc} quantiles (table 7).

220

221 In the sensitivity analysis without the cohort-limiting factors as baseline ECGs and potassium
222 blood tests, the cohort consisted of 15.675 individuals, and the baseline characteristics are
223 shown in Supplementary, table 1. In adjusted models of the sensitivity analysis, PRS_{QTc} ≥80 %
224 could predict short-term mortality with OR 1.23 (P-value = 0.053), PRS_{QTc} ≥90 % could
225 predict short-term mortality with OR 1.52 (P-value = 0.002) and PRS_{QTc} ≥99 % could predict
226 short-term mortality with OR 1.69 (P-value = 0.12) (table 2 in Supplementary).

227 When analyzing the deceased in this cohort, it was not observed that the individuals in the top
228 PRS_{QTc} quantiles had lower ages at death (table 3 in Supplementary). When investigating the
229 prevalence of cancer in the top PRS_{QTc} quantiles in this cohort, this study observed increased
230 prevalence in the top quantiles: The prevalence of cancer in PRS_{QTc} ≥80 % is 42.5 % and 33.9
231 % in the PRS_{QTc} < 80 % group (P-value = 0.0001). In the deceased individuals, cancer was not
232 significantly more prevalent in the top PRS_{QTc} quantiles (table 3, Supplementary).

233

234 **Discussion**

235 A case-control study investigating whether PRS_{QTc} is of predictive value to the outcome ΔQTc
236 QTc and short-term mortality in first-time users of QT-prolonging psychoactive medication
237 with a known risk of TdP was conducted. This study found that individuals in the top quantiles
238 of PRS_{QTc} may be at risk of greater positive ΔQTc and 30-day-mortality following initiation of
239 treatment.

240 An abstract presented in the American Heart Association in November 2023 of a prospective
241 cohort study investigating the predictive value of PRS_{QTc} to the outcome delta-QTc in
242 individuals exposed to Sotalol found similar results (22).
243 It is interesting to discuss the predictive value of PRS_{QTc} in relation to a baseline ECG measured
244 prior to initiation of QTPM. Our results show that the more prolonged the QT-interval is in a
245 baseline ECG, the lower the risk of greater Δ QTc, -0.54 ms ($< 1 * 10^{-4}$). For instance, for every
246 increase in baseline QTcF, the odds of ≥ 60 ms in Δ QTc decrease by a factor 0.93 (P-value = $<$
247 $1 * 10^{-4}$). This finding prompts that baseline ECGs cannot predict the individuals at risk of
248 greater QT-prolongation when exposed to QTPM. In contrast, when belonging to the top \geq
249 80 % in PRS_{QTc}, the odds of ≥ 60 ms in delta-QTcF increase by a factor 4.88 (P-value 0.019). In
250 comparison, when affected by hypokalemia, the odds of ≥ 60 ms in delta-QTcF increase by a
251 factor of 9.38 (P-value = 0.00014).
252 Results from the interaction analysis show that individuals in the top ≥ 80 % PRS_{QTc} with a
253 normal baseline QTcF were the individuals at greatest risk of positive $d\Delta$ QTc when exposed to
254 the QT-prolonging psychoactive drugs.
255 There is no QTc threshold at which TdP is certain to develop, albeit the risk of TdP increases by
256 a twofold to threefold when having a QTc greater than 500 ms. It is also documented that
257 every 10-millisecond increase in QTc, increases the risk of TdP by 5-7 % (23-25).
258 Based on the results of this study, PRS_{QTc} may be a better predictive tool than the baseline ECG
259 when assessing how an individual will respond to QTPM, especially in individuals with normal
260 baseline QTc.
261
262 When stating that PRS_{QTc} may predict 30-day-mortality following initiation of QT-prolonging
263 psychoactive medication, it is important to analyze the baseline characteristics of the studied
264 population. As a baseline ECG and potassium blood test were inclusion criteria in the studied
265 population, most of the individuals originated from the CHB-cohort, which consist of
266 hospitalized patients or outpatients at hospitals. The baseline characteristics of the studied
267 population indicate high frequency of one or more disorders (table 5). This is observed across
268 all PRS_{QTc} groups, though the only variables which are distributed significantly different in the
269 PRS_{QTc} groups are baseline QTcF and cancer: For example, in the group, PRS_{QTc} ≥ 90 %, the
270 mean QTcF was 432.5 ms and the mean QTcF in the <90 % was 420.6ms (P-value=
271 $5.89 * 10^{-14}$). The prevalence of cancer in top PRS_{QTc} ≥ 90 % was 43.9 % and in the <90 %

272 group, the prevalence was 34.7 % (P-value = 0.0002). It has not been previously reported that
273 individuals with long QT syndrome are at increased risk of cancer. However, GWASs of the QT-
274 interval typically find common variants in genes regulating ion-channels, calcium-handling
275 proteins and myocyte structure(11,15,26,27). Both ion channels and calcium-handling
276 proteins are important drivers for hallmarks of cancer as proliferation, apoptosis and
277 migration (28–31). As genomic instability is an important feature of cancer, it is plausible that
278 some variants influencing the phenotype of the QT-interval may also influence the risk of
279 cancer.

280 Though there is an increased prevalence of cancer in the top quantiles in the studied
281 population, there is not a significant increased prevalence of cancer in the top PRS_{QTc} quantiles
282 of the deceased individuals. In models adjusted for all risk factors, PRS_{QTc} ≥ 80 % predicts
283 short-term mortality with OR 1.32 (P-value = 0.089), PRS_{QTc} ≥ 90 % predicts short-term
284 mortality with OR 1.84 (P-value = 0.002) and PRS_{QTc} ≥ 99 % predicts short-term mortality
285 with OR 4.95 (P-value = 0.0093).

286 In the sensitivity analysis including a younger cohort with fewer counts of disorders, PRS_{QTc} ≥
287 90 % could still predict short-term mortality with OR 1.52 (P-value = 0.002).

288 When finding that PRS_{QTc} may both predict the QTc response and short-term mortality
289 following initiation of QTPM, using PRS_{QTc} as a predictive tool in a clinical setting may help
290 prevent sudden deaths associated with QTPM.

291

292 One limitation of this study is the time limit at which the baseline ECG and potassium blood
293 test had to be measured within, as they cannot fully represent the biological conditions in all
294 individuals right before the initiation of the QTPM. Another limitation is that, though, the
295 treatment periods based on the prescriptions were calculated, it cannot be fully validated that
296 the individuals were under influence of the reference drugs when the treatment-ECGs were
297 measured. The main strength of this study is the combination of both clinical, paraclinical and
298 genetic variables in cohorts of reasonable sizes, allowing us to compare baseline ECG and
299 PRS_{QTc} to each other, which has led to one of the novel interesting findings.

300

301 In conclusion, this study found that PRS_{QTc} can be predictive of the QTc response following
302 initiation of QT-prolonging psychoactive drugs with a known risk of Torsade de Pointes. PRS_{QTc}
303 might even be a better predictor of the QTc response compared to the baseline ECG. This study

304 also found that PRS_{QTc} could predict 30-day-mortality after initiation of treatment. If used in a
305 clinical setting, PRS_{QT} may help prevent sudden cardiac deaths associated with QT-prolonging
306 medication.

307

308 **Acknowledgements**

309 I would like to thank Jonas Ghouse, Søren Albertsen-Rand, Henning Bundgaard, Alex Hørby
310 Christensen and Morten Salling Olesen. I would also like to thank deCODE genetics for the
311 work done in Copenhagen Hospital Biobank and the Danish Blood Donor Study.

312

References

1. Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. *JAMA Intern Med* [Internet]. 2020 May 1 [cited 2023 Nov 1];180(5):698–706. Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2762577>
2. Al-Akchar M, Siddique MS. Long QT Syndrome. *StatPearls* [Internet]. 2022 Dec 26 [cited 2024 Jan 7]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441860/>
3. Straus SMJM, Kors JA, De Bruin ML, Van Der Hooff CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol* [Internet]. 2006 Jan 17 [cited 2024 Jan 7];47(2):362–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/16412861/>
4. Klotzbaugh RJ, Martin A, Turner JR. Drug-induced proarrhythmia: Discussion and considerations for clinical practice. *JAAPA* [Internet]. 2020 Feb 1 [cited 2023 Nov 1];33(2):1–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/31990841/>
5. El-Sherif N, Turitto G, Boutjdir M. Acquired long QT syndrome and torsade de pointes. *Pacing Clin Electrophysiol* [Internet]. 2018 Apr 1 [cited 2023 Nov 1];41(4):414–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/29405316/>
6. Weiss JN, Qu Z, Shivkumar K. Electrophysiology of Hypokalemia and Hyperkalemia. *Circ Arrhythm Electrophysiol* [Internet]. 2017 Mar 1 [cited 2023 Nov 2];10(3):675. Available from: <https://www.ahajournals.org/doi/abs/10.1161/CIRCEP.116.004667>
7. Kannankeril P, Roden DM, Darbar D. Drug-Induced Long QT Syndrome. *Pharmacol Rev* [Internet]. 2010 Dec [cited 2023 Nov 20];62(4):760. Available from: </pmc/articles/PMC2993258/>
8. Mahida S, Hogarth AJ, Cowan C, Tayebjee MH, Graham LN, Pepper CB. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. *Journal of Interventional Cardiac Electrophysiology* 2013 37:1 [Internet]. 2013 Mar 21 [cited 2023 Nov 1];37(1):9–19. Available from: <https://link.springer.com/article/10.1007/s10840-013-9779-5>
9. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia. *Cell*. 1999 Apr 16;97(2):175–87.
10. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. *Proceedings of the National Academy of Sciences* [Internet]. 2000 Sep 12 [cited 2023 Nov 1];97(19):10613–8. Available from: <https://www.pnas.org/doi/abs/10.1073/pnas.180223197>
11. Young WJ, Lahrouchi N, Isaacs A, Duong TV, Foco L, Ahmed F, et al. Genetic analyses of the electrocardiographic QT interval and its components identify additional loci and pathways. *Nature Communications* 2022 13:1 [Internet]. 2022 Sep 1 [cited 2024 Jan 7];13(1):1–18. Available from: <https://www.nature.com/articles/s41467-022-32821-z>
12. Sørensen E, Christiansen L, Wilkowski B, Larsen MH, Burgdorf KS, Thørner LW, et al. Data Resource Profile: The Copenhagen Hospital Biobank (CHB). *Int J Epidemiol* [Internet]. 2021 Jun 1 [cited 2023 Nov 2];50(3):719–720E. Available from: <https://pubmed.ncbi.nlm.nih.gov/33169150/>

13. Erikstrup C, Sørensen E, Nielsen KR, Bruun MT, Petersen MS, Rostgaard K, et al. Cohort Profile: The Danish Blood Donor Study. *Int J Epidemiol* [Internet]. 2023 Jun 6 [cited 2024 Jul 23];52(3):e162–71. Available from: <https://dx.doi.org/10.1093/ije/dyac194>
14. Home :: Crediblemeds [Internet]. [cited 2024 Jan 7]. Available from: <https://www.crediblemeds.org/>
15. Hoffmann TJ, Lu M, Oni-Orisan A, Lee C, Risch N, Iribarren C. A large genome-wide association study of QT interval length utilizing electronic health records. *Genetics* [Internet]. 2022 Dec 1 [cited 2023 Nov 2];222(4). Available from: </pmc/articles/PMC9713425/>
16. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature Communications* 2019 10:1 [Internet]. 2019 Apr 16 [cited 2023 Nov 2];10(1):1–10. Available from: <https://www.nature.com/articles/s41467-019-09718-5>
17. Seyerle AA, Sitlani CM, Noordam R, Gogarten SM, Li J, Li X, et al. Pharmacogenomics Study of Thiazide Diuretics and QT Interval in Multi-Ethnic Populations: The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE). *Pharmacogenomics J* [Internet]. 2018 Apr 1 [cited 2023 Nov 2];18(2):215. Available from: </pmc/articles/PMC5773415/>
18. Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM. What Clinicians Should Know About the QT Interval. *JAMA* [Internet]. 2003 Apr 23 [cited 2023 Nov 2];289(16):2120–7. Available from: <https://jamanetwork.com/journals/jama/fullarticle/1357296>
19. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. *Ther Adv Drug Saf* [Internet]. 2012 [cited 2023 Nov 2];3(5):241. Available from: </pmc/articles/PMC4110870/>
20. Darbar D, Kimbrough J, Jawaid A, McCray R, Ritchie MD, Roden DM. Persistent Atrial Fibrillation is Associated with Reduced Risk of Torsades de Pointes in Patients with Drug-Induced Long QT Syndrome. *J Am Coll Cardiol* [Internet]. 2008 Feb 2 [cited 2024 Jan 7];51(8):836. Available from: </pmc/articles/PMC2271078/>
21. Johannsdottir HX, Gudmundsdottir IJ, Karason S, Sigurdsson MI. Association between pre-operative prolonged corrected QT interval and all-cause mortality after non-cardiac surgery. *Acta Anaesthesiol Scand* [Internet]. 2023 Mar 1 [cited 2024 Jul 22];67(3):284–92. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/aas.14178>
22. Lancaster MC, Davogustto GE, Prifti E, Perret C, Funck-Brentano C, Roden DM, et al. Abstract 16962: A Polygenic Predictor of Baseline QT is Associated With Sotalol-Induced QT Prolongation. *Circulation* [Internet]. 2023 Nov 7 [cited 2024 Jan 8];148(Suppl_1). Available from: https://www.ahajournals.org/doi/abs/10.1161/circ.148.suppl_1.16962
23. Schwartz PJ, Woosley RL, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. *J Am Coll Cardiol*. 2016 Apr 5;67(13):1639–50.
24. Li M, Ramos LG. Drug-Induced QT Prolongation And Torsades de Pointes. *Pharmacy and Therapeutics* [Internet]. 2017 Jul [cited 2024 Jan 8];42(7):473. Available from: </pmc/articles/PMC5481298/>
25. Li M, Ramos LG. Drug-Induced QT Prolongation And Torsades de Pointes. *Pharmacy and Therapeutics* [Internet]. 2017 Jul [cited 2024 Jan 8];42(7):473. Available from: </pmc/articles/PMC5481298/>
26. Bihlmeyer NA, Brody JA, Smith AV, Warren HR, Lin H, Isaacs A, et al. ExomeChip-Wide Analysis of 95 626 Individuals Identifies 10 Novel Loci Associated With QT and JT Intervals.

- Circ Genom Precis Med [Internet]. 2018 Jan 1 [cited 2024 Jan 8];11(1):E001758. Available from: <https://pubmed.ncbi.nlm.nih.gov/29874175/>
27. Arking DE, Pulit SL, Crotti L, Van Der Harst P, Munroe PB, Koopmann TT, et al. Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. *Nat Genet* [Internet]. 2014 [cited 2024 Jan 8];46(8):826–36. Available from: <https://pubmed.ncbi.nlm.nih.gov/24952745/>
 28. Prevarskaya N, Skryma R, Shuba Y. Ion channels in cancer: Are cancer hallmarks oncochannelopathies? *Physiol Rev* [Internet]. 2018 Apr 1 [cited 2024 Jan 8];98(2):559–621. Available from: <https://journals.physiology.org/doi/10.1152/physrev.00044.2016>
 29. Bortner CD, Cidlowski JA. Ion channels and apoptosis in cancer. *Philosophical Transactions of the Royal Society B: Biological Sciences* [Internet]. 2014 Mar 3 [cited 2024 Jan 8];369(1638). Available from: </pmc/articles/PMC3917358/>
 30. Stewart TA, Yapa KTDS, Monteith GR. Altered calcium signaling in cancer cells. *Biochimica et Biophysica Acta (BBA) - Biomembranes*. 2015 Oct 1;1848(10):2502–11.
 31. Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. *Acta Pharm Sin B* [Internet]. 2017 Jan 1 [cited 2024 Jan 8];7(1):3. Available from: </pmc/articles/PMC5237760/>

Study of delta-QTc: Before and after initiation of QT-prolonging medication




Figure 1: Selection of the study population with a baseline ECG and on-treatment ECG along with a baseline potassium blood test.

*Normal ECG: No presence of atrial fibrillation/flutter, right or left bundle branch block, pace rhythms, 2. or 3. degree AV block, premature atrial or ventricular extrasystoles, Wolf-Parkinson-White pattern, or poor-quality data. We additionally excluded ECGs with a QRS duration >120 ms, bradycardia (heart frequency, <40) or tachycardia (heart frequency, >110). We also excluded extreme outliers based on the following criteria: QTcFridericia (QTcF) <0.1 % of cohort distribution (<320 milliseconds), and QTcF >99.9 % (>614 milliseconds).

Study of short-term mortality after initiation of QT-prolonging medication




Figure 2: Selection of the study population investigating the outcome: On-treatment, 30-day-mortality.

Linear plot illustrating delta-QTcF after initiation of QT-prolonging medication




Figure 3: Adjusted linear plot showing the absolute delta-QTcF of ECGs measured before and after initiation of QT-prolonging drugs as function of PRS_{QTc}. The plot illustrates the study population in which ECG1 is measured within 18 months before initiation (N=785). ECG2 are on-treatment ECGs obtained within 12 months after initiation of the QT-prolonging drug. The continuous line represents the component plot, and the dashed line represents the residual plot.




Figure 4: This linear plot illustrates that the shorter QTc before initiation of QT-prolonging drugs, the higher the risk of greater Δ QTc after initiation of treatment.

30-day mortality after exposure to QT-prolonging medication




Figure 5: Forest plot showing the AUC of risk factors for mortality and/or prolonged QT-interval after initiation of QT-prolonging medication. The AUC difference of “All except $PRS_{QTc} \geq 90\%$ ” and “All including $PRS_{QTc} \geq 90\%$ ” is statistically significant, though not robust, with a P-value of 0.04.

Covariates	ΔQTc in milliseconds (P-value)
Male	-1.435 (0.6)
Age	0.124 (0.04)
Baseline, QTcF in milliseconds	-0.549 (< 0.001)
IHD	4.1 (0.04)
HF	-0.88 (0.74)
Loop Diuretics or Thiazides	0.7 (0.78)
Additional QT-prolonging drug	-1.25 (0.7)
Hypokalemia, <3.6 mmol/L	5.4 (0.03)
PRS, increase in standard deviation	2.88 (< 0.001)

Table 1: The absolute delta-QTcF in milliseconds of ECGs measured within 18 months before initiation of QT-prolonging medication and within 12 months after initiation of on-treatment ECG. The influence of different QT-prolonging factors on delta-QTcF are shown. The linear model used have additionally been adjusted for PCs 1-10.

Factors influencing delta QT interval (N=785).	≥ 10 ms, OR (P-value)	≥ 20 ms, OR (P-value)	≥ 30 ms, OR (P-value)	≥ 40 ms, OR (P-value)	≥ 50 ms, OR (P-value)	≥ 60 ms, OR (P-value)
Male	0.89 (0.48)	0.81 (0.24)	0.93 (0.74)	1.33 (0.36)	1.41 (0.4)	1.39 (0.55)
Age	1.01 (0.01)	1 (0.24)	1.01 (0.31)	1.02 (0.14)	1.03 (0.12)	1.03 (0.28)
Baseline, QTcF in milliseconds	0.97 (< 1 * 10 ⁻⁴)	0.96 (< 1 * 10 ⁻⁴)	0.96 (< 1 * 10 ⁻⁴)	0.96 (< 1 * 10 ⁻⁴)	0.95 (< 1 * 10 ⁻⁴)	0.93 (< 1 * 10 ⁻⁴)
IHD	1.41 (0.07)	1.4 (0.11)	1.37 (0.23)	1.76 (0.089)	2.09 (0.09)	6.02 (0.003)
HF	1.18 (0.52)	1.12 (0.69)	1.11 (0.78)	1.26 (0.6)	1.33 (0.61)	1.31 (0.72)
Loop Diuretics or Thiazides	1.54 (0.08)	1.19 (0.513)	1.05 (0.88)	1.56 (0.27)	1.25 (0.69)	1.07 (0.93)
Additional QT-prolonging drug	1.11 (0.73)	1.01 (0.97)	0.62 (0.3)	0.15 (0.07)	0.35 (0.34)	0.31 (0.37)
Hypokalemia, <3.6 mmol/L	1.1 (0.68)	1.14 (0.16)	1.62 (0.12)	2.72 (0.007)	3.82 (0.003)	9.38 (0.00014)
PRS ≥ 80th percentile	1.95 (0.00075)	2.11 (0.0005)	1.84 (0.02)	2.36 (0.015)	2.4 (0.06)	4.88 (0.019)
PRS ≥ 90th percentile	1.48 (0.15)	1.91 (0.03)	1.39 (0.4)	1.39 (0.56)	1.38 (0.68)	1.93 (0.56)
PRS ≥ 99th percentile	2.05 (0.35)	4.54 (0.047)	0 (0.97)	0 (0.99)	0 (0.99)	0 (0.99)
PRS ≤ 20th percentile	0.75 (0.17)	0.72 (0.16)	0.52 (0.04)	0.79 (0.54)	0.82 (0.69)	0.86 (0.83)

ΔQTc	≥ 10 ms, OR (P-value)	≥ 20 ms, OR (P-value)	≥ 30 ms, OR (P-value)	≥ 40 ms, OR (P-value)	≥ 50 ms, OR (P-value)	≥ 60 ms, OR (P-value)
PRS \geq 80th percentile	1.9 (0.001)	2.07 (<0.001)	1.78 (0.03)	2.6 (0.004)	2.3 (0.076)	5.9 (0.015)

ΔQTc	≥ 10 ms, OR (P-value)	≥ 20 ms, OR (P-value)	≥ 30 ms, OR (P-value)	≥ 40 ms, OR (P-value)	≥ 50 ms, OR (P-value)	≥ 60 ms, OR (P-value)
PRS \geq 90th percentile	1.56 (0.00075)	2.04 (0.017)	1.4 (0.4)	1.77 (0.27)	1.44 (0.64)	2.28 (0.48)

ΔQTc	≥ 10 ms, OR (P-value)	≥ 20 ms, OR (P-value)	≥ 30 ms, OR (P-value)	≥ 40 ms, OR (P-value)	≥ 50 ms, OR (P-value)	≥ 60 ms, OR (P-value)
PRS \geq 99th percentile	2.19 (0.3)	4.7 (0.041)	1.84 (0.02)	0 (0.98)	0 (0.98)	0 (0.99)

Table 2: Results showing the OR of the outcomes, delta-QTc: ≥ 10 ms, ≥ 20 ms, ≥ 30 ms, ≥ 40 ms, ≥ 50 ms and ≥ 60 ms, from logistic models including variables potentially influencing delta-QT. All the logistic models used have additionally been adjusted for PCs 1-10.

Baseline QTcF in ms	Interaction P-value, $\geq \Delta 10$ ms	Interaction P-value, $\geq \Delta 20$ ms	Interaction P-value, $\geq \Delta 30$ ms	Interaction P-value, $\geq \Delta 40$ ms	Interaction P-value, $\geq \Delta 50$ ms	Interaction P-value, $\geq \Delta 60$ ms
Normal QTc: 380-449 (M), 390-459 (F)	0.01	0.059	0.034	0.079	0.16	0.0098
Borderline QTc: 450-469 (M), 460-479 (F)	0.28	0.78	0.46	0.99	1	1
Long QTc: ≥ 470 (M), ≥ 480 (F)	0.14	0.15	0.31	0.31	1	1

Table 3: Analyzing the interaction of $PRS_{QTc} \geq 80\%$ and intervals of QTcF from ECGs measured within 18 months before initiation, using the binary outcome: Delta-QTc: ≥ 10 ms, ≥ 20 ms, ≥ 30 ms, ≥ 40 ms, ≥ 50 ms and ≥ 60 ms. The ECGs used after initiation have all been on-treatment and within 12 months after initiation. The models have been adjusted for PCs 1-10.

Baseline Characteristics N=3001	PRS_{QTc}, <80 % N=2403	PRS_{QTc} ≥ 80 % N=598	P-value	PRS_{QTc}, <90 % N=2703	PRS_{QTc} ≥ 90 % N=298	P-value	PRS_{QTc}, <99 % N=2983	PRS_{QTc} ≥ 99 % N=18	P-value
Age (mean)	71.15	71.01	0.46	70.17	71.17	0.25	71.13	70.27	0.9
Male (N, %)	1203 (50 %)	295 (49.3 %)	0.78	1356 (50.16)	142 (47.6)	0.44	1493 (50 %)	5 (27.8 %)	0.1
Cancer (N, %)	814 (33.9 %)	254 (42.5 %)	0.0001	937 (34.7)	131 (43.9 %)	0.0002	1060 (35.5%)	8 (44.4 %)	0.59
Stroke (N, %)	319 (13.3 %)	71 (11.9 %)	0.39	351 (13 %)	39 (13.08 %)	1	388 (13 %)	2 (11.1 %)	1
COPD (N, %)	364 (15.14%)	91 (15.15 %)	1	415 (15.3 %)	42 (14.09 %)	0.62	454 (15.2 %)	3 (16.7 %)	1
Ischemic Heart Disease (N, %)	631 (26.3 %)	150 (25 %)	0.59	695 (25.7 %)	86 (28.86 %)	0.27	780 (16.1 %)	1 (5.5 %)	0.086
Heart Failure (N, %)	324 (13.5 %)	69 (11.5 %)	0.23	358 (13.2 %)	35 (11.7 %)	0.52	392 (13.1 %)	1 (5.5 %)	0.55
Renal Insufficiency (N, %)	239 (9.9 %)	58 (9.7 %)	0.9	272 (10 %)	25 (8.4)	0.41	297 (9.9 %)	0 (0 %)	0.3

Hepatic Insufficiency (N, %)	35 (1.46 %)	10 (1.67 %)	0.84	42 (15.5)	3 (10 %)	0.63	45 (1.5 %)	0 (0 %)	1
Additional QT-prolonging drug (N, %)	172 (7.15 %)	47 (7.1 %)	0.61	195 (7.2 %)	24 (8 %)	0.68	218 (7.3 %)	1 (5.5 %)	1
Loop-diuretics or Thiazides (N, %)	327 (13.6 %)	80 (13.4)	0.94	373 (13.8 %)	34 (11.4 %)	0.29	405 (13.6 %)	2 (11.1 %)	1
Hypokalemia, P <3.6 (N, %)	305 (12.7 %)	80 (13.4)	0.7	343 (12.7 %)	42 (14.01 %)	0.55	380 (12.7 %)	5 (27.8 %)	0.12
QTcF, ECG (mean in ms)	419.9	429.3	3.04 * 10 ⁻¹⁵	420.6	432.5	5.89 * 10 ⁻¹⁴	421.7	437.7	0.017

Table 4: The baseline characteristics of the study population used to calculate OR of 30-day-mortality after initiation of the QT-prolonging medication.

Risk factors for mortality and prolonged QT-interval	OR for 30-day-mortality	Confidence Interval	P-value
Age	1.02	1.01-1.04	0.00018
Male	1.7	1.28-2.25	0.0002
Cancer	6.44	4.77-8.69	<1*10 ⁻⁴
Stroke	1.2	0.81-1.77	0.36
COPD	1.24	0.87-1.76	0.23
Ischemic Heart Disease	0.94	0.68-1.29	0.7
Heart Failure	1.02	0.67-1.55	0.9
Renal Insufficiency	1.07	0.7-1.65	0.75
Hepatic Insufficiency	2.95	1.32-6.62	0.0008
Additional QT-prolonging drug	1.2	0.73-1.94	0.47
Loop-diuretics or Thiazides	1.97	1.4-2.79	0.0001
Hypokalemia (P <3.6)	1.74	1.24-2.45	0.0013
QTcF, ECG	0.99	0.99-1	0.0029
PRSQ_{Tc} ≥ 80 %	1.32	0.96-1.81	0.089
PRSQ_{Tc} ≥ 90 %	1.84	1.26-2.74	0.002
PRSQ_{Tc} ≥ 99 %	4.95	1.48-16.56	0.0093

Table 5: Results of on-treatment, 30-day-mortality in the study population of first-time users of QT-prolonging medications. In the logistic models, the risk models in the left column were included. In addition, all the models have been adjusted for PCs 1-10.

30-Day Mortality	Rest, <80 % N=2403	PRS_{QTc} ≥ 80 % N=598	P-value	Rest, <90 % N=2703	PRS_{QTc} ≥ 90 % N=298	P-value	Rest, <99 % N=2983	PRS_{QTc} ≥ 99 % N=18	P-value
N (%)	202 (8.4 %)	66 (11 %)	0.0523	227 (8.4 %)	41 (13.76 %)	0.0078	263 (8.8 %)	5 (27.8 %)	0.016
Age at death	75.18	73	0.146	75.26	71.68	0.036	74.9	63.4	0.028
Male	57.6 %	60.4 %	0.79	137 (60 %)	23 (56 %)	0.73	158 (- %)	≤ 5 (- %)	-
Cancer	153 (75.74 %)	51 (77.27 %)	0.93	170 (74.9 %)	34 (82.9 %)	0.36	199 (-%)	≤ 5 (- %)	-

Table 6: Results showing characteristics of the individuals deceased within 30-days after initiation of the QT-prolonging in the study population.